Physician profile
Dixie G Clement
NPI 1851517734
$964.37
in general payments reported to CMS, 2019-2025
17 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131 · 2020: $110 · 2021: $50.10 · 2022: $85.87 · 2023: $205 · 2024: $255 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $245.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $158.64 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Abbvie INC. | $122.93 | 2021-2024 | Vraylar, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $99.05 | 2019-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $61.71 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $43.79 | 2022-2025 | Zoryve |
| Astrazeneca Pharmaceuticals Lp | $41.74 | 2019-2020 | |
| Exact Sciences Corporation | $37.33 | 2023-2024 | Cologuard Collection Kit |
| Allergan, INC. | $26.77 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.29 | 2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.99 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $18.16 | 2023 | Trelegy Ellipta, Shingrix |
| Idorsia Pharmaceuticals US INC | $17.48 | 2024 | Quviviq |
| Amgen INC. | $15.57 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.99 | 2025 | Caplyta |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.05 | 2022 | |
| Cardiovascular Systems INC. | $9.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dixie Clement listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.